A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

This study is testing a new medication called Denikitug, either alone or combined with other therapies, to see how well it helps treat advanced colorectal cancer that has not responded to previous treatments. The goal is to see if these combinations can help the immune system better recognize and fight cancer cells.

You may be eligible if you have advanced colorectal cancer that is 'microsatellite stable' and has continued to grow after previous standard chemotherapy. You must have received no more than two prior systemic treatments and be in generally good health regarding your heart, lungs, and digestive system.

Participants will receive either Denikitug alone or in combination with other proven cancer medications through an intravenous drip. You will have regular check-ups, imaging scans like CTs or MRIs, and blood tests to monitor how your body and the cancer are responding to the treatment.

The study is currently recruiting participants at research centers in North Haven, Connecticut, and Boston, Massachusetts. It is an active Phase 2 trial exploring new options for patients with this specific type of cancer.